Key result
Infusion of levosimendan without a loading dose resulted in persistent symptomatic and echocardiographic improvement without major side effects in two children with cancer and acute heart failure.
Why the study?
Does levosimendan improve symptoms and cardiac function in children with cancer and severe acute chemotherapy-induced heart failure?
Case Report (n=2)
Does levosimendan improve symptoms and cardiac function in children with cancer and severe acute chemotherapy-induced heart failure?
Levosimendan may be a safe and effective adjunctive therapy for severe acute chemotherapy-induced heart failure in pediatric cancer patients unresponsive to standard inotropes.
Answers are grounded in this paper and cite their sources.
May support levosimendan in refractory pediatric chemotherapy-induced heart failure; hypothesis-generating and should not yet change practice.
We report the use of levosimendan in two febrile, neutropenic children with cancer - one post bone marrow transplant - with acute heart failure following chemotherapy. Initial management with epinephrine, milrinone, and diuresis was unsuccessful. Infusion of levosimendan without a loading dose was added to the ongoing heart failure therapy, which resulted in persistent symptomatic and echocardiographic improvement without major side effects.
No takes yet. Share an insight, caveat, or question.
Tosoni et al. (2013) conducted a case report in Severe acute cardiac dysfunction (n=2). Levosimendan was evaluated on Symptomatic and echocardiographic improvement. Infusion of levosimendan without a loading dose resulted in persistent symptomatic and echocardiographic improvement without major side effects in two children with cancer and acute heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: